Cargando…

Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice

The dipeptidyl peptidase-4 inhibitor linagliptin promotes β-cell survival and insulin secretion by prolonging endogenous glucagon-like peptide 1 (GLP-1) action and therefore helps to maintain normoglycemia in diabetic patients. The effect of linagliptin on glucagon-producing α cells, however, was no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yanqing, Fava, Genevieve E., Wu, Meifen, Htun, Wynn, Klein, Thomas, Fonseca, Vivian A., Wu, Hongju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686619/ https://www.ncbi.nlm.nih.gov/pubmed/29264448 http://dx.doi.org/10.1210/js.2017-00253

Ejemplares similares

Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors
por: Zhang, Yanqing, et al.
Publicado: (2017)

Erratum. GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. Diabetes 2019;68:34–44
por: Zhang, Yanqing, et al.
Publicado: (2020)

Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
por: Haak, Thomas
Publicado: (2015)

Linagliptin use in older individuals with type 2 diabetes
por: Pratley, Richard E
Publicado: (2014)

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
por: Guedes, Erika Paniago, et al.
Publicado: (2013)

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
por: von Websky, Karoline, et al.
Publicado: (2013)

Linagliptin alleviates fatty liver disease in diabetic db/db mice
por: Michurina, Svetlana V, et al.
Publicado: (2016)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
por: Dietrich, Nadine, et al.
Publicado: (2016)

Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice
por: Fushimi, Yoshiro, et al.
Publicado: (2021)

Linagliptin-related pancreatitis in a diabetic patient with biliary calculus: A case report
por: Sevencan, Nurhayat Ozkan, et al.
Publicado: (2018)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
por: Retlich, Silke, et al.
Publicado: (2015)

Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting β Cell Survival and α-to-β Cell Transdifferentiation
por: Parajuli, Keshab R., et al.
Publicado: (2020)

Mild Pancreatitis Induced by Linagliptin Revealed by a Medication Review
por: Gidda, Harish, et al.
Publicado: (2023)

Clinical utility and tolerability of linagliptin in diabetic patients
por: Maxwell, Lauralee Gordon, et al.
Publicado: (2013)

Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice
por: Nagai, Takuo, et al.
Publicado: (2016)

Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humans
por: Tammen, Harald, et al.
Publicado: (2023)

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2012)

Pax4 in Health and Diabetes
por: Ko, Jenna, et al.
Publicado: (2023)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
por: Korbut, Anton I., et al.
Publicado: (2020)

Acute Pancreatitis Induced by Linagliptin: A Rare but Dangerous Side Effect
por: Sharko, Artem, et al.
Publicado: (2021)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice
por: Hansen, Henrik H., et al.
Publicado: (2021)

Regeneration of Pancreatic Non-β Endocrine Cells in Adult Mice following a Single Diabetes-Inducing Dose of Streptozotocin
por: Zhang, Yanqing, et al.
Publicado: (2012)

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
por: Hoimark, Lene, et al.
Publicado: (2012)

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
por: Gallwitz, Baptist
Publicado: (2015)

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
por: Groop, P-H, et al.
Publicado: (2014)

Effects of Linagliptin and Pioglitazone on Fracture Healing in an Experimental Type 2 Diabetes Rat Model
por: Mraja, Hamisi M, et al.
Publicado: (2022)

Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis
por: Adhikari, Juthi, et al.
Publicado: (2023)

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride
por: Darsalia, Vladimer, et al.
Publicado: (2013)

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
por: Lietzau, Grazyna, et al.
Publicado: (2018)

Clinical efficacy of linagliptin combined with irbesartan in patients with diabetic nephropathy
por: Liu, Jie, et al.
Publicado: (2022)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
por: Rauch, Thomas, et al.
Publicado: (2012)

Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
por: Kern, Matthias, et al.
Publicado: (2012)

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin
por: Freeman, Jeffrey S
Publicado: (2013)

Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
por: Terawaki, Yuichi, et al.
Publicado: (2015)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
por: Farr, Amanda M, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k5cteh43nm0s1ujgrmvdn62k5v